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Background: Angiotensin II receptor blockers (ARBs) have a potential role in reducing 
inflammation and fibrosis. We have integrated systems and molecular biology approaches to 
investigate the therapeutic potential of ARBs in preventing post-surgical adhesion band 
formation.  
Material and method: we have followed the ARRIVE guidelines point by point during 
experimental studies. Telmisartan (1 and 9 mg/kg), valsartan (1 and 9 mg/kg) and Losartan (1 
and 10mg/kg) were administered intraperitoneally in different groups of male albino Wistar rat. 
After 7 days of treatment, macroscopic evidence and score of fibrotic bands based on scaling 
methods was performed. Moreover, the anti-inflammatory and anti-fibrosis effects of 
Telmisartan on reduction of fibrotic bands were investigated by using histopathology, ELISA, 
and Real time PCR methods. 
Result: Telmisartan, but not Losartan or Valsartan, prevented the frequency as well as 
the stability of adhesion bands. Telmisartan appears to elicit anti-inflammatory responses by 
attenuating sub-mucosal edema, suppressing pro-inflammatory cytokines, decreasing pro-
inflammatory cell infiltration, and inhibiting oxidative stress at the site of peritoneal surgery. We 
also showed that Telmisartan prevents fibrotic adhesion band formation by reducing excessive 
collagen deposition, and suppression of pro-fibrotic genes expression at the peritoneum 
adhesion tissues.  
Conclusion: These results support the potential application of Telmisartan in preventing 
post-surgical adhesion band formation by inhibiting key pathological responses of inflammation 
and fibrosis in post-surgery patients. 






Peritoneal adhesions are pathological fibrotic bands that may develop in various 
conditions including endometriosis, chemical peritonitis and surgical trauma (1). Adhesion 
formation is a major factor causing mortality and morbidity in 90 to 95% of patients undergoing 
pelvic or abdominal surgery (2). Intra-abdominal adhesion contributes to increasing post-
operative clinical difficulties including female infertility (3), pelvic pain (4), intestinal obstruction 
(5), and bleeding (6). Although, some barrier/separation materials, for example, Seprafilm and 
Interceed (FDA approved), as well as other strategies such as administration of anti-
inflammatory, fibrinolysis and antibiotic drugs, are clinically accessible; however, these 
interventions are far from ideal and result in limited success (7-9). A better understanding of the 
pathogenesis and cellular and molecular mechanisms responsible for post-operative adhesions 
formation would help to develop the effectiveness of the treatment methods. 
Surgical trauma or damage to the intra-abdominal cavity caused by surgery increases 
the secretion of cytokines contributing to the migration of inflammatory cells and fibroblast to 
injured peritoneum (10). Activated fibroblasts and mesothelial cells release pro-fibrotic 
transforming growth factor β (TGF-β) in peritoneal cavity (11, 12) which has a significant role in 
tissue repair and wound healing processes (13). Abnormal secretion and aberrant regulation of 
the TGF-β/ Smad signaling pathway increase the expression of fibrotic genes and accumulation 
of extracellular matrix (ECM) deposition leading fibrogenesis and adhesion bands formation (14, 
15).   
Identifying suitable agents for preventing post-surgical intra-abdominal adhesion 
formation remains an important clinical need. The literature has described cross-talk between 
angiotensin and TGF-β/Smad signaling can affect the fibrosis in different organs. It has been 
shown that angiotensin II receptor blockers (ARBs) have a potential role in reducing fibrosis 
through Angiotensin-TGF-β1 crosstalk in heart tissue of post-myocardial infarction (MI) rats (16). 
Moreover, the angiotensin type I receptor (ART1) reduced the activation of the Smad pathway in 
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fibrosis conditions in renal injury  (17). Furthermore, Uhal et al. showed that angiotensin 
receptor antagonists are capable of reducing Idiopathic Pulmonary Fibrosis in man (18). In the 
present study, we hypothesized that the administration of ARBs may potentially reduce post-
surgical abdominal adhesions formation. We investigated the therapeutic effects of three of the 
most important ART1 antagonists including Telmisartan, Losartan, and Valsartan in post-




Material and Methods  
Materials 
Telmisartan, Losartan, and Valsartan were purchased from MedKoo Bioscience 
(Shanghai, China). Haematoxylin and Eosin and all reagents for catalase, superoxide dismutase 
(SOD), Malonyl dialdehyde (MDA) and total thiol reactions were obtained from Sigma Co (Saint 
Louis, MO). Interferon-γ (IFN-γ), interleukin-6 (IL-6), tissue necrosis factor-alpha (TNFα) and 
transforming growth factor-β (TGF-β) ELISA kits were all provided from eBioscience company 
(San Diego, CA). RNeasy Mini kit and cDNA Reverse Transcription Kit were purchased from 
Qiagen Inc. (Hilden, Germany) and TaKaRa Bio (Shiga, Japan) respectively. 
 
Animal experiment 
All experimental studies we performed according to the ARRIVE guidelines (Ref). 
Albino Wistar male rats weighing 230-250 g were purchased from the Pasture Institute (Tehran, 
Iran).  Animals were maintained in standard temperature (24 ± 20 C) with 60 ± 5% humidity and 
12 hr light/dark cycle. All rats had free access to tap water and were fed standard rat chow. The 
animal experiments were accomplished by the protocol of Care and Use of Laboratory Animals 
from Mashhad University of Medical Sciences (MUMS). All animal procedures were carried out 
according to the guidelines approved by the Ethics Committee of Mashhad University of Medical 
Sciences. 
 
The post-surgical adhesion band model procedure 
Surgical procedure for post-surgical adhesion band formation was described by 
Hemadeh et al. (8). Briefly, After 7 days, the formation of intraperitoneal adhesions occurs with 
high probability (up to 95%) in the positive control group. Maintenance anesthesia was 
performed by using ketamine (15-40 mg/kg) administered intra-peritoneally during surgery (19).  
Then abdominal skin shaved and cleaned with Povidone-iodine before the procedure. The 
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abdomen was opened with a ‘U' shaped incision and cecal abrasion by surgical gauze was 
continued until the presence of hemorrhagic points in abrasion sites. 3-0 chromic and 3-0 nylon 
catguts were used to suture the abdominal muscles and abdominal skin, respectively.  
Surgical groups 
Forty-eight rats were divided by double-blind randomize into eight groups (n=6) as 
below; 1) positive control (Cnt+) group (surgical abrasion and peritoneal adhesion treated with 
ARBs solvent, dimethylsulfoxide (DMSO); 2) sham group (Cnt-) (surgical incision with no 
abrasion or adhesion); 3 and 4) Telmisartan Low and High Dose (TLD) and (THD) groups 
(surgical abrasion treated with 1 and 9 mg/kg Telmisartan, respectively) (20-22); 5 and 6) 
Valsartan Low and High Dose (VLD) and (VHD) groups (surgical abrasion treated with 1 and 9 
mg/kg Valsartan) (23); and 7 and 8) Losartan Low and High Dose (LLD) and (LHD) groups 
(surgical abrasion treated with 1 and 9 mg/kg Losartan) (24). Schematic representation of the 
study protocol has been shown in Fig. 1A. ARBs drugs dissolved in DMSO and administered by 
intraperitoneal (i.p) injection for 7 days (25). Drugs administration was performed in animal room 
at the morning. At the end of the treatment process, rats were sacrificed and tissue samples 
were stored in 10% formalin or rapidly frozen in liquid nitrogen. During the experimental period, 
no complications including wound infection, intra-abdominal infection, bleeding or high dose 
toxicity was observed in the different treatment groups.  
 
Evaluation of adhesion scores 
At the end of experiments, all rats were anesthetized and laparotomy was performed via 
a U-shaped incision. The peritoneum was opened to evaluate intra-abdominal adhesions 
according to the adhesions grade criteria described by Nair et al. (26) and Leach et al. (27). 
Frequency and stability of the adhesion bands were analyzed in a blinded fashion (Table 1). 
 
Hematoxylin and Eosin (H&E) and Masson’s trichrome staining 
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Cross-sections of adhesion tissues between the cecum and abdominal wall were 
obtained and preserved in formalin 10%. H&E and Masson’s trichrome staining was performed 
to evaluate the inflammatory cells infiltration and collagen deposition as described (28). 
 
Enzyme-Linked Immunosorbent Assay (ELISA) analysis 
Tissue specimens were collected, homogenized, centrifuged in 4000rpm for 15 min, then 
supernatant isolated to evaluate tissue concentration of TNF-α, IFN-γ, TGF-β, and IL-6 by rat 
ELISA kits (Invitrogen eBioScience, German) according to the manufacturer's instructions. 
Briefly, the target-specific antibody has been pre-coated in the wells of the supplied micro 
plates. Samples, standards, or controls are then added into these wells and bind to the 
immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) 
antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to 
produce measurable signal. The intensity of this signal is directly proportional to the 
concentration of target present in the original specimen.  
 
Oxidative stress markers analysis 
 For measuring MDA level 1 ml of 10% tissue homogenates were mixed with 2 mL of 
thiobarbituric acid (TBA), Trichloroacetic acid (TCA), and HCL solution in boiling water for 45 
minutes and centrifuged for 10 minutes. Next, the absorbance at 535 nm was read and the MDA 
level was measured by C (M) = A ⁄1.65×105 (29) 
Total thiol group was estimated by DTNB (Di-Tio nitro benzoic acid) reagent. DTNB 
reacts with SH groups and produces the color yellow complex. In this line, 1ml of Tris-EDTA 
buffer (pH = 8.6) was added to tissue homogenate and the specimen absorbance read at 412 
nm against Tris-EDTA buffer alone (A1). Next, 20 μl of DTNB reagents were added to this 
solution and incubated at room temperature for 15 minutes. Then, the sample absorbance was 
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measured again (A2). The absorbance of DTNB reagent was used as a blank (B). Total thiol 
concentration (mM) was calculated by SH (mM) = (A2-A1-B) × 1.07 / (0.05 × 13.6.) (30). 
The catalase (CAT) enzyme activity was detected as described previously by Aebi et al. 
The rational of this method was based on the hydrolyzation of H2O2 in phosphate buffer, pH 7.0, 
and reducing absorbance at 240 nm. The enzyme activity can be estimated by the conversion of 
H2O2 to H2O and O2 in 1 min under standard situation (31).  
SOD enzyme activity was measured with colorimetric Madesh assay using 96 micro 
plates. In this method, SOD in sample tissues use superoxide anion so prevent reaction 
between O2- and MTT (32). 
 
Real-Time Polymerase-Chain-Reaction (RT-PCR) 
Real-time-PCR was performed as previously described (33). Briely, Total RNA from 
adhesion tissues was extracted using total RNA Mini Kit (Yekta Tajhiz Azma, Tehran). Next 
cDNA was synthesized according to reverse transcription kit protocol (TAKARA, Dalian, China).  
Real-time quantitative PCR (qPCR) was performed using SYBR Green qPCR Master Mix on a 
LightCycler Roche. A melting analysis was performed for evaluation the specificity of the 
amplification. Results were normalized against GAPDH and calibrated to control group. A 
relative expression was quantified using the 2−ΔCt method. The PCR primer sequences are 
shown in Table 2. 
 
Gene expression data analysis 
Alterations in the gene expression following treatment of the HT29 colon cancer cell line 
with 10 µl Telmisartan (LINCSCP_126712) or losartan (LINCSCP_126358) for 24 hours were 
extracted from iLINCS database (34, 35). Significantly up or down-regulated genes with -
0.5<log (fold change)<0.5 and adjusted p-value <0.05 were subjected to Enrichr (36) for 
pathway enrichment analysis using Wiki Pathways library. L1000CDS2 (37) online tool was 
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used to identify drugs with known mode of action that results in similar gene expression 
signature. Pheatmap package in R was used to create heatmaps (38). STRING (39) 11.0 
database was used to create a network of protein-protein interactions with selected nodes. 
Interaction data obtained from text-mining were excluded from the network to increase the 
strength of predicting interactions. 
 
Data analysis 
All the data were expressed as the means ± standard deviation (SD). Normality of our 
data was analyzed using Shapiro-wilk normality test. Statistical differences were determined 




Telmisartan treatment decreased adhesion bands scores in a dose-dependent manner 
The surgical procedure and anesthetic induction were successfully performed and all 
animal models survived to seven days after the second laparotomy. The representative 
illustration of adhesion band grades has been presented in (Fig. 1B). According to Nair (26) and 
Leach (27) scoring systems, we quantitatively evaluated the frequency and rigidity of adhesion 
bands in all groups (Fig. 1C-D). Our results showed that the median of both adhesion scores 
was significantly lower in THD-treated rats compared with positive control (Cnt+) group (P < 
0.05). No significant differences were observed between TLD, VLD, VHD, LLD, LHD groups 
with Cnt+. No adhesion band was formed in the abdomen incision in Cnt- group. Since there 
was no difference between Valsartan- or Losartan-treated groups compared to the Cnt+ group, 
we focused on the therapeutic potency of Telmisartan in the rest of the manuscript. 
 
Telmisartan reduced tissue damage-associated inflammatory responses in the adhesion rat 
model 
Inflammation is one of the key factors in the pathogenesis of post-surgical adhesion 
bands formation. To determine the effect of angiotensin II receptor antagonist, Telmisartan, on 
adhesion bands-associated inflammation, peritoneum adhesion tissues were stained with 
Hematoxylin and Eosin (H&E) to analyze the pathological responses and morphological 
changes in adhesion rat models. Results showed that both low (1mg/kg) and high (9mg/kg) 
doses of Telmisartan were able to reduce the infiltration of inflammatory cells into the injured 
site but a high dose of Telmisartan was much more effective (Fig. 2A).  
Next, we compared the level of pro-inflammatory cytokines including IFN-γ, IL-6, and 
TNF-α in peritoneum adhesion tissues homogenates between the THD, and TLD with the 
positive control group. We showed that high dose of Telmisartan could significantly reduce IL-6 
and TNF-α concentrations (p value<0.05) (Fig. 2B and C). THD decreased INF-γ level but the 
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difference was not statistically significant (Fig. 2D). These results showed that the protective 
effects of Telmisartan against post-surgical adhesion band formation could be at least partially 
mediated by its anti-inflammatory responses in the rat model. 
 
Effects of Telmisartan on oxidative stress markers 
To further investigate the anti-inflammatory effects of Telmisartan in post-surgical 
adhesion bands, the effect of this angiotensin II receptor antagonist was evaluated on the 
oxidative stress markers in an adhesion rat model. Consistent with previous results, Telmisartan 
significantly decreased the level of MDA, an oxidant marker, in TLD (4.09 ± 0.99) and THD 
(2.32 ± 0.54) groups compared to the Cnt+ group (7.25 ± 1.30) (p<0.05) (Fig. 3A). Furthermore, 
the concentrations of total thiol, as well as the activity of catalase and superoxide dismutase 
(SOD) enzymes, anti-oxidant markers, were measured in the peritoneum adhesion tissues 
homogenates in different groups. Our results showed that total thiol, catalase and SOD indexes 
were significantly higher in THD (1.83 ± 0.65, 0.41 ± 0.01 and 2.19 ± 0.06, respectively) and 
TLD cases (0.98 ± 0.20, 0.27 ± 0.06 and 1.41 ± 0.24, respectively) than the positive control 
group (0.2 ± 0.028, 0.16 ± 0.013 and 0.7 ± 0.23, respectively) (p<0.05) in tissue homogenates 
(Fig. 3B-D), supporting the anti-inflammatory properties of Telmisartan in post-surgical adhesion 
rat model. 
 
Telmisartan prevents adhesion formation by attenuating fibrosis in the rat model  
Due to the significance of fibrosis in post-surgical adhesion band formation, Masson’s 
trichrome staining was used to assess the collagen deposition in adhesion tissue sections. We 
showed that high dose of Telmisartan decreased fibrosis and tissue damage significantly (Fig. 
4A). Consistent with results obtained from Masson’s trichrome staining we showed that the 
mRNA levels of collagen 3.1 and 1.1 were significantly reduced in animals receiving a high dose 
of Telmisartan (9mg/kg) compared to the Cnt+ group (Fig. 4B and C).  
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Furthermore, studies are supporting the role of TGF-β in fibrotic-related complications 
(40). Since ARBs potentially affect the TGF-β signaling pathway through angiotensin-TGF-β 
crosstalk, the protein level of this marker was compared in the peritoneum adhesion tissue 
homogenates between groups. As presented in Fig. 4D only high dose of Telmisartan reduced 
TGF-β concentration in tissue homogenate samples, suggesting the anti-fibrotic effects of 
Telmisartan in preventing adhesion band formation. 
 
Analysis of gene expression signature of Telmisartan 
Given the observed difference in the higher efficacy of Telmisartan compared to 
Losartan in inhibiting the formation of adhesive bands, we analyzed the gene expression 
signature of the Telmisartan and Losartan at 10µl in HT29 colon cancer cell line using iLINCS 
database (Figure 5A-C). Following pathway enrichment analysis, we observed that in Losartan 
treated cells, cell cycle and G1 to S transition (adjusted p-value =1.01E-04) were the most 
significantly enriched pathways while for Telmisartan, apoptosis-related pathways (adjusted p-
value<0.05) and corticotropin-releasing hormone (adjusted p-value = 3.70e-02) were 
significantly observed (Figure 5B and C).  
We hypothesized that such difference between the two ARB drugs may be due to the 
additional targeting of PPAR-γ by Telmisartan but not Losartan and Valsartan (41). To test this 
hypothesis, we used L1000CDS2 online tool to identify other drugs with a known mode of action 
that mimics gene expression signature induced by Telmisartan or Losartan (Table 3). 
Accordingly, we observed that for Telmisartan, the top-ranked drugs were Rosiglitazone and 
Pioglitazone, known PPAR-γ agonists and 15-deoxy-delta 12, 14-prostaglandin J2 which has 
anti-inflammatory properties. For Losartan, however, Zolanitidine (histamine H2 receptor 
inhibitor), Betamethasone (glucocorticoid) and Thalidomide (immunosuppressive and anti-
angiogenic) were observed. These results further strengthened the hypothesis that the 
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difference in higher efficiency of Telmisartan over Losartan was due to agonist of PPAR-γ by 
Telmisartan. 
 We further assessed the interaction between direct targets of Telmisartan (ATGR1 and 
PPAR-γ) and the proteins whose expressions were altered in adhesive bands in our study 
including CAT, SOD, TNF, IL6, TGFβ, COL3A1 and COL1A1 using the network of protein-
protein interactions (Supplementary Fig. 1). Interestingly, among different biological processes, 
we observed significant enrichment of regulation of cell death (GO: 0010941) with FDR = 2.07e-
07 and regulation of inflammatory response (GO:0050727) with FDR=6.71e-05, suggesting that 
anti-adhesive properties of Telmisartan may be through modulation of inflammation and 




 We have evaluated the effect of three Angiotensin II receptor blockers including 
Telmisartan, Losartan, and Valsartan in the adhesion rat model. We showed that only 
Telmisartan could significantly prevent post-surgical adhesion band formation in the rat model. 
Further studies showed that Telmisartan could decrease the adhesion-related inflammatory 
responses through reduction of inflammatory cell infiltration into damage site, reducing the 
expression level of inflammatory cytokines, and modulating the oxidant/anti-oxidant agents. 
Moreover, we showed anti-fibrotic effects of Telmisartan possibly by inhibiting pro-fibrotic agents 
such as TGF-β and collagen expression. These findings support the therapeutic potency of 
Telmisartan in decreasing post-surgical adhesion formation.    
Peritoneal adhesion band formation is a common complication for patients undergoing 
abdominal surgery (42). When the peritoneum is injured, inflammatory cells as well as 
fibroblasts, are recruited to the damaged area and inflammation occurs in a large range (43, 44) 
and the inflammatory cytokines such as IL-6 and TNF-α significantly released. Also, it has been 
shown that oxidative stress markers such as MDA play an important role in adhesion formation 
(45). Moreover, overexpression of TGF-β enhances pathophysiological activities through ECM 
deposition and tissue remodeling in this condition (46). Several studies are showing that the 
renin-angiotensin system is involved in fibrosis via inducing collagen synthesis, increasing 
growth factors (47, 48), and stimulating macrophages and fibroblasts to release TGF-β (47, 49). 
 Xuesong et al. demonstrated that Telmisartan attenuates peritoneal dialysis-induced fibrosis by 
decreasing TGF-β via angiotensin type I receptor (AT1R) blockade and activation of peroxisome 
proliferator-activated receptor-γ (PPAR-γ) in experimental rat model (50). Arab et al. showed 
that Telmisartan attenuated inflammation and oxidative stress indexes in inflammatory bowel 
disease (IBD) in colitis rat model (51). Furthermore, the anti-inflammatory effects of Telmisartan 
have been shown in the acute model of inflammation (52). In line with these results, we showed 
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that Telmisartan can effectively inhibit the formation of adhesion bands by inhibiting fibrotic and 
inflammatory cytokines, factors involved in tissue remodeling, and oxidant markers.  
Dose estimation always requires careful consideration about the difference in 
pharmacokinetics and pharmacodynamics among species (53). The tolerance and metabolism 
of drugs in animals are different from human. Many differences in anatomy, physiology, and 
biochemistry between laboratory animals and humans show a different response between 
animal species and humans (54, 55). Selected doses were based on previous studies for 
Telmisartan, losartan and valsartan in rat models. Experimental studies have demonstrated that 
the lethal dose 50%, amount of the substance required (usually per body weight) to kill 50% of 
the test population, for Losartan, Telmisartan, and valsartan is about 2000, 150-200, and 
600mg/kg, respectively (56-58). The doses for these drugs in our study were much lower than 
these concentrations. Thus, during the experimental period, none of animals were killed in 
different treatment groups. Moreover, no signs of unusual behavior, or organs dysfunction 
related to the toxicity of the drugs were observed in rats. 
Investigating the affinity of angiotensin II receptor type I antagonists showed a high 
interaction between Telmisartan and this receptor, compared to valsartan and Losartan (59),  
which may be attributed to the more potent of Telmisartan in decreasing adhesion bands in the 
rat model. Moreover, in another study administration of Telmisartan notably diminished the 
inflammatory responses in pulmonary tissue, while no such effects were shown for Valsartan 
treatment in the same doses (60). Moreover, enrichment of the apoptosis pathway in the gene 
expression data raised the hypothesis that Telmisartan may balance the proliferation and 
apoptosis of macrophages and fibroblasts that are accumulated at the site of surgery. 
Post-surgical adhesion formation is a current problem in almost all of organs such as 
visceral/intra-abdominal or pelvic (61), uterus (62), tendon (63), kidney and urological (64, 65) 
surgeries. Formation of fibrotic bands leads to organs dysfunction causing many pathological 
conditions for patients. In present study, Telmisartan could show therapeutic potential to 
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decrease pathological conditions and fibrotic bands in rat model so using this drug in clinical 
trials studies and combinations with standard protocol like Seprafilm or anti-inflammatory or anti-
fibrotic drugs can help protective effects to prevent post-surgical adhesion formation. Further 
(pre-) clinical investigations should be performed to better determine the clinical significance of 
ARBs against adhesion band formation in post-surgical adhesion band formation during 
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Figure 1. Telmisartan attenuates the incidence and rigidity of peritoneum adhesion 
bands. A) A Schematic representation of the study protocol. B) Telmisartan administration 
dose-dependently reduced the adhesion bands formation, compared to other groups. (C-D) The 
incidence C) and rigidity D) of adhesion bands were significantly decreased by high dose of 
Telmisartan, compared to control (Cnt+) group.  
 
Figure 2. Telmisartan reduced the inflammatory responses in adhesion rat model. (A) 
Hematoxylin and eosin (H&E) staining of intra-abdominal adhesion tissues revealed remarkable 
infiltration of leukocytes (arrows) into damage site in untreated group than treated ones. Higher 
dose of Telmisartan represented lower morphological damages. Also, H& E staining shows that 
the muscularis propria (astrix) is adhered to the skeletal muscle by fibrotic tissue. (B-D) The 
effects of high and low dose of Telmisartan on protein concentration of IL-6 (B), TNF-α (C) and 
IFN-γ (D) in tissues homogenates were compared with Cnt+ group. *p<0.05; **p<0.01. 
 
Figure 3. The effect of Telmisartan on oxidant/anti-oxidant balance in peritoneum 
adhesion bands. (A-D) The concentration of MDA (A) and total Thiol (B) as well as Catalase 
(C) and Superoxide Dismutase (SOD) (D) enzymes activities were compared between Cnt+, 
THD and TLD groups. *p<0.05; **p<0.01; ***p<0.001. 
 
Figure 4. Telmisartan prevent fibrogenesis in adhesion rat model. (A) Masson’s trichrome 
staining displayed a higher collagen deposition in Cnt+ group than Telmisartan-treated groups. 
Collagen-type fibrosis is shown in blue fiber (Arrows). (B-C) The mRNA expression of Collagen 
3.1 (B) and Collagen 1.1 (C) in adhesion tissues were quantified and compared between THD-
23 
 
treated group and Cnt+ group. (D) Telmisartan in high doses could significantly reduce TGF-β 
concentration in tissue homogenates. *p<0.05; **p<0.01; ***p<0.001. 
 
Figure 5. Assessment of gene expression changes induced by Telmisartan versus 
Losartan. A) Heatmap representing the expression values of genes perturbed by Telmisartan 
and Losartan at concentration of 10µM. B) Pathway enrichment analysis of significantly altered 
genes by Telmisartan using WikiPathways library in Enrichr database and comparing the 
expression values of genes within the significant pathways in Losartan gene expression 
signature. C) Pathways associated with significantly altered genes following treatment of HT29 
cells with Losartan versus Telmisartan treated cells. Vertical axis demonstrates the significance 
of enrichment and shown as –log of adjusted p-value. Adjusted P-value <0.05 was assumed to 
be significant.  
 
Supplementary figure 1. Protein-protein interaction network for direct and indirect targets of 
Telmisartan obtained from STRING 11.0 database 
